Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO4588161 dose-finding combination study in treatment-naive genotype 1 chronic hepatitis C
2006-006604-11Phase 2Completed
- Sponsor
- Roche
- Start
- Aug 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of balapiravir in hepatitis C virus infection (2 arms), sponsored by Roche. Primary endpoint: Sustained virologic response at 24 weeks after end of treatment. Started Aug 2007; status: completed.
02
Drugs
balapiravir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2006-006604-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006604-11.